Healthcare Industry News: drug-eluting stent
News Release - October 12, 2006
David Kandzari, M.D., International Expert in Interventional Cardiology, Named Chief Medical Officer of Cordis CardiologyMIAMI, Oct. 12 (HSMN NewsFeed) -- Cordis Corporation today announced the appointment of David E. Kandzari, M.D., to the position of Chief Medical Officer, effective early December 2006. In this newly created role, Dr. Kandzari will oversee the clinical and medical affairs activities for the cardiology division of Cordis Corporation.
"I look forward to joining the Cordis cardiology team," said Dr. Kandzari. "The company has been at the forefront of breakthrough clinical development and as a physician, I share the company's mission to defeat cardiovascular disease. I am very eager and enthusiastic to take on these challenges as part of the Cordis team."
Dr. Kandzari was most recently the John B. Simpson Assistant Professor of Interventional Cardiology and Genomic Sciences and Assistant Professor of Medicine and Molecular Genetics and Microbiology at the Duke University Medical Center in Durham, N.C. He also served in national leadership roles in clinical trials for numerous cardiovascular products.
"We are pleased to have Dr. Kandzari join the Cordis cardiology family," said Todd Pope, Worldwide President, Cordis Cardiology, a division of Cordis Corporation. "His experience and leadership abilities in cardiovascular clinical trials and physician education will be a tremendous asset to the company as we continue to highlight the growing body of clinical evidence for the CYPHER® Sirolimus-eluting Coronary Stent, as well as next generation drug-eluting stents."
Dr. Kandzari is the author of numerous journal articles in the area of cardiovascular disease and is the recipient of many academic society honors. In 2003, he received the Thomas J. Linnemeier Spirit of Interventional Cardiology Young Investigator Award. A noted lecturer in a range of cardiology topics, Dr. Kandzari has lectured at conferences throughout the United States and abroad.
A graduate of Duke University with Bachelor of Arts degrees in zoology and Germanic languages, Dr. Kandzari received his medical degree from the Duke University School of Medicine. Following his medical residency at The Johns Hopkins University School of Medicine, he returned to the Duke University School of Medicine as a General and Interventional Cardiology Fellow, and remained as a faculty member until his new appointment at Cordis
About Cordis Corporation
Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in developing and manufacturing interventional vascular technology. Through the company's innovation, research and development, physicians worldwide are better able to treat the millions of patients who suffer from vascular disease.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.